

 SERVIZIO SANITARIO REGIONALE EMILIA-ROMAGNA Azienda Ospedaliero-Universitaria di Modena Policlinico Servizio Ricerca e Innovazione	CONFLITTO DI INTERESSI NELLA UNITÀ DI FASE I (CENTRALE-OPERATIVA) E NEL CLINICAL TRIAL QUALITY TEAM	SRI PS05 Rev. 0 / 2016 Pag 7/8
--	---	--

DICHIARAZIONE PUBBLICA SUL CONFLITTO DI INTERESSI (vs 0 del 08/01/2016)

Nome

LAURA

Cognome

BRISTOT

Qualifica

STUDY COORDINATOR

Ente di appartenenza AOU POLICLINICO DI MODENA - UO
GASTROENTEROLOGIA

Si prega di elencare di seguito ogni eventuale interesse nell'industria farmaceutica (se necessario utilizzare più moduli).

Impegno nell'industria farmaceutica nel corso degli ultimi cinque anni:

- Tutte le attività svolte (direttamente o indirettamente) per ditte farmaceutiche (o per loro conto, in questo caso specificare il proprio ruolo e le attività svolte e indicare il nome del prodotto e la natura del lavoro svolto), sia che tali attività abbiano comportato o meno remunerazione regolare o occasionale, in denaro oppure in natura, fra le quali:
 - Partecipazione al processo decisionale interno di una ditta farmaceutica (per es. partecipazione al consiglio di amministrazione, direzione esecutiva o non esecutiva);
- Appartenenza permanente o temporanea al personale di una ditta farmaceutica. Altre attività svolte all'interno di una ditta farmaceutica (per es. tirocinio) sono ugualmente soggette a dichiarazione;
- Lavoro di consulenza o di altro genere, appaltato da ditte farmaceutiche

NA

Interessi finanziari nel capitale di un'industria farmaceutica:

Nome dell'industria:

Tipo di azione: NA Numero di azioni:

Altri rapporti con l'industria farmaceutica:

- Ogni tipo di assistenza e sostegno ricevuto dall'industria durante i precedenti 5 anni, comprendente o meno i benefici pecuniari o materiali, diretti o indiretti del tipo:
 - Borse di studio o di ricerca istituite dall'Industria

 SERVIZIO SANITARIO REGIONALE EMILIA-ROMAGNA Azienda Ospedaliero-Universitaria di Modena Policlinico Servizio Ricerca e Innovazione	CONFLITTO DI INTERESSI NELLA UNITÀ DI FASE I (CENTRALE-OPERATIVA) E NEL CLINICAL TRIAL QUALITY TEAM	SRI PS05 Rev. 0 / 2016 Pag 8/8
---	---	--

- o Fellowship o sponsorizzazioni sovvenzionate dall'industria farmaceutica.

NA

Altri interessi o fatti che si ritiene debbano essere portati a conoscenza, ivi compresi elementi relativi ai componenti del proprio nucleo familiare (i componenti del nucleo familiare sono: il coniuge, il/la compagno/a e i figli a carico che vivono sotto lo stesso tetto dell'interessato (*non è necessario menzionare il nome di tali persone*)).


NA

Il sottoscritto dichiara di non detenere, a sua conoscenza, altri interessi diretti o indiretti nell'industria farmaceutica oltre a quelli menzionati.

Dichiara inoltre che si impegna a presentare una nuova dichiarazione pubblica di conflitto di interessi qualora dovessero risultare nuovi o ulteriori interessi, tali da dover essere portati a conoscenza.

Inoltre, il sottoscritto autorizza la pubblicazione della presente dichiarazione sul sito internet dell'Azienda Ospedaliero-Universitaria Policlinico di Modena nella sezione dedicata.

In fede



26/09/2016 Data

CLINICAL DATA MANAGER AND STUDY COORDINATOR

PERSONAL INFORMATION

Surname/ First name

BRISTOT, LAURA

Nationality

Italian

Address

Via dei loraghi 27, 41124 Modena

Date of Birth

14th June 1981

Telephone

Mobile: +39/3289232976

E-mail

laurabris@gmail.com
laura.bristot@unimore.it

PROFESSIONAL EXPERIENCE

- August 2014 – Present

Data manager and Study Coordinator at the Gastroenterology Department of the University Clinic Hospital of Modena.

JOB DESCRIPTION: Data management and study coordinator in no profit and sponsored trials. General Manager Prof. Erica Villa.

- April 2013 – July 2014

Farmacist at Coop Estense

- April 2013 – March 2013

Attendant regulatory affairs and pharmacovigilance at Monico Spa, Via Ponte di Pietra 7 Mestre, Venezia

JOB DESCRIPTION: Drug dossier submission for approval in Italy and abroad. Report of cases of adverse events related to drugs. Revision of package inserts and drug labels, primary and secondary canning.

- December 2010 – December 2012

Data manager and Study Coordinator at the Cardiology Department of the University Clinic Hospital of Ferrara.

JOB DESCRIPTION: Data management and study coordinator in no profit and sponsored trials.

General Manager Prof. Roberto Ferrari, Cath. Lab. Director of Hemodynamic Doc. Marco Valgimigli.

- April 2009 – November 2010

Data manager and Study Coordinator of sponsored and no profit clinical trials in cardiology. Fondazione Anna Maria Secchi per il cuore (FASC), MTA Italy.

JOB DESCRIPTION: Data management and study coordinator in no profit and sponsored trials.

General Manager Prof. Roberto Ferrari, Cath. Lab. Director of Hemodynamic Doc. Marco Valgimigli.

- May 2008 – March 2009

Research Associate at the Department of Clinical and Experimental Medicine - Sant'Anna hospital in Ferrara



TOPIC OF RESEARCH: Evaluation of the effects of antimuscarinic compounds on inflammatory responses and remodelling in alveolar macrophages and bronchial smooth muscle cells from patients with COPD and smokers with normal lung function.
Prof. Alberto Papi.

• November 2007 – April 2008

Research Associate at the Asthma Center of the - Sant'Anna hospital in Ferrara
TOPIC OF RESEARCH: Association of increased CCL5 and CXCL7 chemokine expression with neutrophil activation in severe stable COPD.

• September 2006 – July 2007

Research Associate at Biochemical Department at Ferrara University
Research funded by the ISS as part of the National AIDS Research
"Etiopathogenesis, immunological and virological studies of HIV / AIDS"

TOPIC OF RESEARCH: "The role of bioactive peptides in immunogenesis generated from the degradation of Tat protein of HIV by the proteasome".
"Consorzio Ferrara Ricerche" based in Ferrara, via Savonarola 9, and operational headquarters in Via Saragat 1. Coordinator and Head of Prof. Riccardo Gavioli the Department of Biochemistry and Molecular Biology, University of Ferrara. The activity was mainly carried out at the Laboratory of Cellular and Molecular Oncology of the University of Ferrara.

ACADEMIC BACKGROUND

• 2008 – 2010

Masters Degree II Level "SCHOOL OF CLINICAL RESEARCH AND EPIDEMIOLOGICAL".

Thesis Title: "Feasibility Study on Pharmacogenetics".

• 2007

Professional pharmacist Qualification, University of Ferrara (Italy).

• 2000 – 2006

Degree in Chemistry and Pharmaceutical Technologies (5-year-long programme), University of Ferrara (Italy).

Thesis Title: "In vivo degradation of the Tat protein of HIV".
Grade: 103/110.

• 2006

Experimental Dissertation 12 Months c/o Biochemistry and Biology Lab, Ferrara University Supervisor Prof. Riccardo Gavioli, dal titolo "Degradation in vivo of the protein Tat of HIV".

• 1995 – 2000

High School, Liceo Classico Statale Tiziano di Belluno (Italy).

• 2003

Erasmus student at the University of Salamanca

Metti 1 riga con le materie piu importanti che hai fatto + spanish language course .

SELECTED PUBLICATIONS



J Thromb Thrombolysis. 2012 Oct;34(3):318-25

The in vitro effects of verbascoside on human platelet aggregation.

Campo G, Marchesini J, Bristot L, Monti M, Gambetti S, Pavasini R, Pollina A, Ferrari R

JACC Cardiovasc Interv. 2012 Mar;5(3):268-77. doi: 10.1016/j.jcin.2012.01.006.

Prasugrel versus tirofiban bolus with or without short post-bolus infusion with or without concomitant prasugrel administration in patients with myocardial infarction undergoing coronary stenting: the FABOLUS PRO (Facilitation through Aggrastat By drOpping or shortening Infusion Line in patients with ST-segment elevation myocardial infarction compared to or on top of PRasugrel given at loading dOse) trial.

Valgimigli M, Tebaldi M, Campo G, Gambetti S, Bristot L, Monti M, Parrinello G, Ferrari R; FABOLUS PRO Investigators.

JACC Cardiovasc Interv. 2011 Jan;4(1):66-75. doi: 10.1016/j.jcin.2010.09.017.

Prediction of 1-Year Clinical Outcomes Using the SYNTAX Score in Patients With Acute ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention A Substudy of the STRATEGY (Single High-Dose Bolus Tirofiban and Sirolimus-Eluting Stent Versus Abciximab and Bare-Metal Stent in Acute Myocardial Infarction) and MULTISTRATEGY (Multicenter Evaluation of Single High-Dose Bolus Tirofiban Versus Abciximab With Sirolimus-Eluting Stent or Bare-Metal Stent in Acute Myocardial Infarction Study) Trials.

Garg S, Sarno G, Serruys PW, Rodriguez AE, Bolognese L, Anselmi M, De Cesare N, Colangelo S, Moreno R, Gambetti S, Monti M, Bristot L, Bressers M, Garcia-Garcia HM, Parrinello G, Campo G, Valgimigli M; STRATEGY and MULTISTRATEGY Investigators.

Thorax. 2009 Nov;64(11):968-75. Epub 2009 Aug 23

Association of increased CCL5 and CXCL7 chemokine expression with neutrophil activation in severe stable COPD.

Di Stefano A, Caramori G, Gnemmi I, Contoli M, Bristot L, Capelli A, Ricciardolo FL, Magno F, D'Anna SE, Zanini A, Carbone M, Sabatini F, Usai C, Brun P, Chung KF, Barnes PJ, Papi A, Adcock IM, Balbi B.

J Biol Chem. 2008 Aug 4.

Role of xanthine-oxidase activation and reduced glutathione depletion in rhinovirus induction of inflammation in respiratory epithelial cells.

Papi A, Contoli M, Gasparini P, Bristot L, Edwards MR, Chicca M, Leis M, Ciaccia A, Caramori G, Johnston SL, Pinamonti S.

Research Centre on Asthma and COPD, University of Ferrara, Ferrara 44100.



LABORATORY METHODS

- Details of ...
 - Working in a sterile environment
 - Cultivation of primary and immortalized cell lines
 - Separation of blood components through Percoll or HISTOPAQUE and obtaining PBMCs from monocytes and dendritic cells through layering Ficoll
 - Cytometry FACS analysis
 - Analysis and separation of cytoplasmic and nuclear proteins
 - Western blotting and densitometry of the bands.
 - Immunostaining
 - Test activities
 - Testing of cytotoxicity
 - INF- γ ELISPOT assay
 - ELISA
 - Immunohistochemistry and immunocytochemistry
 - PCR
 - Processing of surgical pieces for classical histology and immunohistochemistry
 - Use of the microtome

ADDITIONAL SKILLS

- Software
 - Microsoft Office: Word, Excel, Power Point, and Access.
 - HTLM
 - Software for statistical analysis: STATA 6 and MedCalc.
 - I am proficient in managing and creating databases.

LANGUAGES

- ITALIAN
 - Mother tongue.

- ENGLISH

Reading: Excellent	Writing: Good	Speaking: Good
--------------------	---------------	----------------

 - Certificate issued by the 'Language Institute of Ferrara Marco Polo
 - Three-month stay in London. Certificate from Exeter High School.

- SPANISH

Reading: Proficient (C2)	Writing: Advanced (C1)	Speaking: Fluent (C2)
--------------------------	------------------------	-----------------------

ADDITIONAL INFORMATION

- Abstract of my post-degree dissertation: Feasibility Study on Pharmacogenetics"



Purpose of Research:

Verify the feasibility of determining the gene polymorphic CYP2C19 in consecutive patients undergoing PCI in the clinical routine.

Results:

The study supports the hypothesis that it is now possible to obtain real-time information about the genetic polymorphism of CYP2C19 gene, a few hours after clopidogrel.

The possibility that genetic information will influence clinical practice in the first hours after administration of the treatment is a reality that merits further investigation.

- **Abstract of my degree dissertation: "In vivo degradation of the Tat protein of HIV"**

Purpose of research:

- Characterization of an inducible cellular system for the expression of Tat
- Definition of a standardized protocol for the degradation of this protein in vivo
- Assessment of the stability of the protein synthesized endogenously by the cell transfected U-2OS-Tat
- Analysis of the role of the proteasome in the degradation of Tat
- Analysis of the role of the lysosomal degradation of Tat.

Results:

- System characterization of inducible expression of Tat protein in human osteosarcoma cells U-2OS-Tat.
- Definition of a standardized protocol: titration and kinetics of ponasterone A, which causes the system U-2OS cell-Tat.
- Definition of the kinetics of appearance of the Tat protein after stimulation with ponasterone A and kinetics of disappearance of the protein after an interruption of stimulation.
- The proteasome has an essential role in the degradation of Tat
- Lysosomal system has only a marginal role in the degradation of Tat
- Formulation of the hypothesis that the degradation products of Tat are more active and efficient forms of the protein.

Laboratory methods learned:

Manual work under the hood and in sterile environments

Cytoplasmic and nuclear cell lysis

Western blotting

Purification of the proteasome through the column

Test Activities

- Immunoprecipitation using protein A conjugated to sepharose

AUTORIZZO IL TRATTAMENTO DEI MIEI DATI PERSONALI, COME DA
LEGGE 196/03 IN MATERIA DI PRIVACY

03/01/2016

Laura